Jefferies Maintains a 'Hold' on Alexion Pharmaceuticals (ALXN); Q4 Soliris Sales Beat; FY12 Sales Guidance Slightly Higher
ALXN Hot Sheet
Rating Summary:9 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Jefferies maintains a 'Hold' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target raised from $58 to $68.
Jefferies analyst says, "Solid 4Q (non-GAAP EPS of $0.41 vs. our/cons of $0.36/$0.34) resulted from ~4% higher Soliris sales of $228M. Its strong fundamentals & scarcity value in the sector warrant a premium valuation for ALXN. However, its ever-increasing lofty valuation (trading at ~14x 2012E revenue vs. ~7x for peer average) is hard to embrace, keeping us on the sidelines. Increasing Price Target on increased Soliris sales estimates and ENB-0040 potential."
"For 2013/2014/2015, we are increasing our total Soliris sales estimates by ~8%/8%/7% to $1.30B/$1.57B/$1.91B, respectively (vs. consensus of $1.30B/$1.50B/$1.72B). Included in the estimates are our 2012-2015 sales estimates in the aHUS indication of $50M/$100M/$174M/$254M, respectively. FY12 guidance for non-GAAP EPS is $1.60-$1.70."
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $80.41 yesterday, with a 52 week range of $43.78-$105.00.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Jefferies analyst says, "Solid 4Q (non-GAAP EPS of $0.41 vs. our/cons of $0.36/$0.34) resulted from ~4% higher Soliris sales of $228M. Its strong fundamentals & scarcity value in the sector warrant a premium valuation for ALXN. However, its ever-increasing lofty valuation (trading at ~14x 2012E revenue vs. ~7x for peer average) is hard to embrace, keeping us on the sidelines. Increasing Price Target on increased Soliris sales estimates and ENB-0040 potential."
"For 2013/2014/2015, we are increasing our total Soliris sales estimates by ~8%/8%/7% to $1.30B/$1.57B/$1.91B, respectively (vs. consensus of $1.30B/$1.50B/$1.72B). Included in the estimates are our 2012-2015 sales estimates in the aHUS indication of $50M/$100M/$174M/$254M, respectively. FY12 guidance for non-GAAP EPS is $1.60-$1.70."
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $80.41 yesterday, with a 52 week range of $43.78-$105.00.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results
- Barclays Raises Estimates on Williams-Sonoma (WSM); Encouraging Q1 Results
- Barclays Maintains an 'Overweight' on Camelot Information Systems (CIS); Q1 Trends Mostly In-line
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
